methyl (2R)-2-(docosa-4,7,10,13,16,19-hexaenoylamino)-3-[[(2R)-2-[(2-hydroxybenzoyl)amino]-3-methoxy-3-oxopropyl]disulfanyl]propanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (2R)-2-(docosa-4,7,10,13,16,19-hexaenoylamino)-3-[[(2R)-2-[(2-hydroxybenzoyl)amino]-3-methoxy-3-oxopropyl]disulfanyl]propanoate
• 化学式: C₃₇H₅₀N₂O₇S₂
• 分子量: 698.9
• InChiKey: UTRZYRRXAJZPNJ-ACHIHNKUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  48
• 可旋转键数：
  26
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  182
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：EP2949344A2

  公开（公告）日：2015-12-02

  The present invention relates to targeting an intracellular enzyme for release of covalently linked bioactives which results in a synergistic effect between the bioactives. The present invention relates to the use of bioactives that are directly connected covalently or through a covalent molecular linker which have increased therapeutic activity when released as the free bioactives by intracellular enzymes as compared to when the bioactives are administered individually (i.e. not covalendy linked). Further, methods are described of administering to patients in need thereof, bioactives as linked bioactives having increased therapeutic activity. Accordingly, this invention also relates to methods of treating patients for certain diseases.

  本发明涉及靶向细胞内酶释放共价连接的生物活性物质，从而使生物活性物质之间产生协同效应。本发明涉及直接共价连接或通过共价分子连接体连接的生物活性物质的使用，与单独施用生物活性物质（即未共价连接）相比，这些生物活性物质在作为游离生物活性物质被细胞内酶释放时具有更高的治疗活性。此外，本发明还描述了向有需要的患者施用生物活性物的方法，这些生物活性物作为连接的生物活性物具有更高的治疗活性。因此，本发明还涉及治疗患者某些疾病的方法。